Benzinga | Jul 24, 2020 08:21AM EDT

HC Wainwright & Co. Maintains Buy on Arcturus Therapeutics, Raises Price Target to $78

HC Wainwright & Co. analyst Ed Arce maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target from $62 to $78.